Celebrating 10 Years of Residency Program Excellence
2023 is a year of celebration at Navitus. Not only is it the 20th anniversary of our founding, but 2023 also marks 10 years of Navitus' residency...
Humira Biosimilars – Update for October Formularies
Our recent August Pharmacy and Therapeutics (P&T) Committee meeting reviewed the release of various Humira® biosimilars. Staying true to our...
Legal Ease: A Navitus Government Affairs Update
In an ever-changing legislative landscape, we want to help our clients and partners stay informed of the latest happenings and how proposed policies...
Humira Biosimilars – Summer of Blockbuster Releases for Navitus to Review
This summer has seen a continuation of the long-awaited market entry of Humira® (adalimumab) biosimilars. As of July 1, nine additional biosimilars...
Transforming Access to Pharmacy Benefits: 2022 Drug Trend Report
We are pleased to share our 2022 Drug Trend Report with you. This year's report highlights our success in managing pharmacy benefit costs for our...
Employee Spotlight: George Hepburn
We had the pleasure of connecting with our new Chief Financial Officer, George Hepburn, to discuss what excites him about his new role, what inspires...
Employee Spotlight: Ken Goodnight
We recently sat down with Ken Goodnight to discuss his key priorities as Chief Transformation & Digital Officer and to learn about his professional...
Humira Biosimilars Enter the Marketplace – Update on Navitus’ Review
The market entry of biosimilars to Humira® (adalimumab) is long-awaited. These products have the potential to improve affordability in the near- and...
Five Forecasts and Takeaways for Plan Sponsors in 2023
As we enter 2023, David Fields is sharing his top forecasts and takeaways for plan sponsors and the PBM industry.
Employee Spotlight: Shelly McAdoo
As we continue our employee spotlight series, we are excited to highlight Shelly McAdoo, Navitus’ new Diversity, Equity and Inclusion (DEI) Senior...
Understanding the Inflation Reduction Act of 2022
Navitus’ Vice President of Government Relations, Robyn Crosson, shares her insight into the Inflation Reduction Act and how it will impact our...
Key Findings: 2021 Navitus Drug Trend Report
This week we provide an overview of our 2021 drug trend and client savings with insights for 2022 and beyond.
